MedLife said it was looking to sign a syndicated loan arrangement with Banca Comerciala Romana (BCR), as coordinator, mandated lead arranger, documentation agent, facility & security agent and lender, BRD Groupe Societe Generale, Banca Transilvania and Raiffeisen Bank as lead arrangers and lenders.
New funding would be used for the consolidation and expansion of the group by developing medical units such as MedPark, the development of programs and projects in the pandemic context, projects related to prevention, oncology and medical radiotherapy, tech and digitization, and to continue research activities.
Medlife said continuing its mergers and acquisitions program remains and the group is in advanced talks for 3-4 deals domestically and 1-2 regionally.
“Research initiatives started since the beginning of last year, consistently and high conducted, have positioned MedLife as a regional pandemic watchdog. We have taken this role very seriously and that is why we aim to intensify our efforts in the research area. We have decided to invest between EUR3 and 5 million for the arrangement of a new biosafety III laboratory where we will work for the first time with live viruses. The land and part of the buildings have already been acquired, and the new unit being next to the group’s central laboratory. The new laboratory will be part of MedPark and will become the most modern research genetics laboratory, virology and molecular biology in Romania,” said Mihai Marcu, President and CEO of MedLife Group.
MedLife Group ended 2020 with consolidated pro-forma sales of EUR251 million, up 25.5% on the year, which makes it one of the largest players at regional level.
“Probably the biggest achievement of MedLife group in 2020 is the scientific, research activities and informing the population and authorities on the evolution of strains from various countries, the seroprevalence acquired after the disease or as a result of vaccination, and the evolution of the pandemic in general. We will continue to be deeply engaged in this process in the years to come,” said Marcu.
For 2021, MedLife expects to maintain its current EBITDA margin and sees 15% growth in consolidated sales.